MetLife Investment Management’s Vera Therapeutics VERA Stock Holding History

MetLife Investment Management’s Portfolio VERA Stock Details VERA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.36M	Buy	33,805 +3,342	+11%	+$144K	0.01%	1259
2025 Q4	$1.54M	Sell	30,463 -608	-2%	-$21.6K	0.01%	1208
2025 Q3	$903K	Hold	31,071	–	–	﹤0.01%	1505
2025 Q2	$732K	Buy	31,071 +4,664	+18%	+$105K	﹤0.01%	1477
2025 Q1	$634K	Sell	26,407 -396	-1%	-$12.7K	﹤0.01%	1598
2024 Q4	$1.13M	Buy	26,803 +4,025	+18%	+$178K	0.01%	1348
2024 Q3	$1.01M	Hold	22,778	–	–	0.01%	1384
2024 Q2	$824K	Buy	22,778 +2,125	+10%	+$84.3K	﹤0.01%	1445
2024 Q1	$891K	Buy	20,653 +2,434	+13%	+$86.7K	0.01%	1362
2023 Q4	$280K	Hold	18,219	–	–	﹤0.01%	2045
2023 Q3	$250K	Hold	18,219	–	–	﹤0.01%	2077
2023 Q2	$292K	Buy	18,219 +9,338	+105%	+$84.3K	﹤0.01%	2031
2023 Q1	$68.9K	Hold	8,881	–	–	﹤0.01%	2676
2022 Q4	$172K	Hold	8,881	–	–	﹤0.01%	2343
2022 Q3	$189K	Hold	8,881	–	–	﹤0.01%	2331
2022 Q2	$121K	Hold	8,881	–	–	﹤0.01%	2632
2022 Q1	$209K	Buy	+8,881	New	+$191K	﹤0.01%	2331

Other funds holding VERA

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MetLife Investment Management's VERA Position: Q1 2026 in Review

MetLife Investment Management increased its Vera Therapeutics (VERA) stake by 11% in Q1 2026, buying an estimated $144K and bringing the position to 33,805 shares worth $1.36M. The position accounts for 0.01% of the portfolio, ranked #1259.

MetLife Investment Management first reported a position in VERA in Q1 2022 and has held it in 17 quarters since. The position peaked at $1.54M in Q4 2025. 229 funds tracked by Wall St. Rank hold VERA as of Q1 2026.

MetLife Investment Management held 33,805 shares of Vera Therapeutics worth $1.36M as of Q1 2026.
MetLife Investment Management bought 3,342 Vera Therapeutics shares in Q1 2026, an estimated $144K.
Vera Therapeutics made up 0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1259 holding.
MetLife Investment Management first reported a position in Vera Therapeutics in Q1 2022 and has held it in 17 quarters since.
MetLife Investment Management's Vera Therapeutics position peaked at $1.54M in Q4 2025.
229 funds tracked by Wall St. Rank held Vera Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.